
SER Stock Forecast & Price Target
SER Analyst Ratings
Bulls say
Serina Therapeutics is viewed favorably because its POZ platform has already shown near zero-order release in SER-214, supporting the core thesis that it can smooth drug exposure, lower peak-driven toxicity, and preserve efficacy across payloads. The lead asset, SER-252, targets a large and underserved advanced Parkinson’s disease market, with early blinded Cohort 1 data showing sustained PK and improvement in motor function in 8 randomized patients (6 active, 2 placebo) without meaningful safety concerns, while the company’s grant revenue is still modest relative to the platform’s upside. With FDA alignment on a 505(b)(2) pathway, first patient-in in Q1 2026, and key readouts expected around YE26 through 1H27, the stock’s appeal rests on a de-risked mechanism, a validated clinical setup, and meaningful platform expansion potential.
Bears say
Serina Therapeutics is a clinical-stage biotechnology company with no approved products, a limited operating history, and significant operating losses since inception, which makes its reliance on future capital raises a key fundamental weakness. The near-term outlook is especially fragile because SER-252 still faces an upcoming P1b readout, where any unexpected safety signal would be a major negative, while even a lack of efficacy would leave the program vulnerable in an intensely competitive Parkinson’s disease landscape. Although the clinical hold has been lifted, the earlier regulatory disruption, ongoing uncertainty around the formulation, and commercialization hurdles such as pricing, reimbursement, and slow primary-care adoption all reinforce a high-risk, execution-dependent story.
This aggregate rating is based on analysts' research of Serina Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Serina Therapeutics, Inc. (SER) Forecast
SER Analyst Forecast & Price Prediction
Start investing in SER
Order type
Buy in
Order amount
Est. shares
0 shares